SEC Comment Letter 0000000000-26-001091 to Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: Jan. 29, 2026 · CIK: 0001671584 · Accession: 0000000000-26-001091
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293010
Letter
January 29, 2026 Marvin White Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed January 28, 2026 File No. 333-293010 Dear Marvin White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mary Wilbourn
Show Raw Text
January 29, 2026
Marvin White
Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-1
Filed January 28, 2026
File No. 333-293010
Dear Marvin White:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mary Wilbourn